Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Vilobelimab is a chimeric human/mouse IgG4‑kappa monoclonal ...
| Class:Id | Summation:9957396 |
|---|---|
| _displayName | Vilobelimab is a chimeric human/mouse IgG4‑kappa monoclonal ... |
| _timestamp | 2025-07-10 11:01:41 |
| created | [InstanceEdit:9957474] Shamovsky, Veronica, 2025-06-18 |
| literatureReference | [LiteratureReference:9957345] Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial [LiteratureReference:9957421] Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients [LiteratureReference:9957445] Regional comparison of efficacy and safety for vilobelimab in critically ill, invasively mechanically ventilated COVID-19 patients [LiteratureReference:9957427] Role of C5a in inflammatory responses [LiteratureReference:375368] The chemotactic receptor for human C5a anaphylatoxin [LiteratureReference:9957499] Complements and Their Role in Systemic Disorders [LiteratureReference:9957451] Editorial: The Role of Complement in Health and Disease [LiteratureReference:9957310] Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis [LiteratureReference:9957403] Novel insights in localization and expression levels of C5aR and C5L2 under native and post-transplant conditions in the kidney [LiteratureReference:9957432] Immunohistochemical identification of complement peptide C5a receptor 1 (C5aR1) in non-neoplastic and neoplastic human tissues [LiteratureReference:9957361] The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19 [LiteratureReference:9957350] Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys [LiteratureReference:9957501] Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study) [LiteratureReference:9957456] Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial |
| modified | [InstanceEdit:9960364] Shamovsky, Veronica, 2025-07-10 |
| text | Vilobelimab is a chimeric human/mouse IgG4‑kappa monoclonal antibody that binds with high affinity to complement component C5a, a protein fragment generated by cleavage of C5 (Vlaar APJ, Witzenrath M et al., 2022; Vlaar APJ, Lim EHT et al., 2022; Lim EHT et al., 2023, 2025). C5a is a potent anaphylatoxin that induces histamine release from mast cells and acts as a strong chemoattractant for leukocytes (reviewed by Guo RF & Ward PA 2005). These pro-inflammatory and chemotactic effects are mediated by the C5a receptor 1 (C5AR1, also known as CD88), a G protein-coupled receptor (Gerard NP and Gerard C, 1991) expressed on neutrophils, monocytes, and other myeloid cells, as well as on non-immune epithelial cells (van Werkhoven MB et al., 2013; Nürg B et al., 2021). Dysregulated signaling through the C5a:C5AR1 axis contributes to excessive inflammation and tissue injury in diverse conditions, including septic shock and viral infections such as severe COVID‑19 (Carvelli J et al., 2020; Bauer M et al., 2021; reviewed by Cedzyński M et al., 2019; Wang SSY et al., 2024). By neutralizing soluble C5a, vilobelimab effectively blocks C5a:C5AR1 signaling, thereby attenuating systemic inflammatory responses in complement-mediated inflammatory conditions (Vlaar APJ, Witzenrath M et al., 2022; Vlaar APJ, Lim EHT et al., 2022; Lim EHT et al., 2023, 2025) without blocking the C5b-mediated formation of membrane attack complex (MAC) (Bauer M et al., 2021; Sun S et al., 2015 (as shown in the African green monkey model of H7N9 virus infection)). In the phase 3 PANAMO trial involving mechanically ventilated COVID‑19 patients, vilobelimab significantly reduced 28‑day and 60‑day mortality and improved survival without increasing infection rates (Vlaar APJ, Witzenrath M et al., 2022; van Amstel RBE et al., 2024; Lim EHT et al., 2025), likely because it preserves MAC formation (Vlaar APJ, Witzenrath M et al., 2022). Pharmacokinetic and pharmacodynamic analyses confirmed effective and sustained C5a suppression, high trough antibody concentrations, and minimal anti‑drug antibody development following administration (Lim et al., 2023). This selected blockade of C5a suggests vilobelimab as a promising therapeutic approach for complement‑mediated inflammatory diseases. |
| (summation) | [Reaction:9957405] C5a binds C5a inhibitor [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Vilobelimab is a chimeric human/mouse IgG4‑kappa monoclonal ... (9957396)
